DEFA14A: Corcept Therapeutics Corrects Share Count in Proxy Statement Ahead of Annual Meeting

Corcept Therapeutics issues a supplement to its proxy statement to correct the number of outstanding shares of common stock as of the record date for the upcoming annual meeting.

Summary

• Corcept Therapeutics has released a supplement to its definitive proxy statement dated April 10, 2024.
• The supplement corrects the number of outstanding shares of common stock as of April 5, 2024, the record date for the Annual Meeting of Stockholders to be held on May 17, 2024.
• The originally stated number of shares was 103,837,166, but the corrected number is 104,082,845.
• This correction affects the sections Shares Outstanding and Quorum, Security Ownership of Certain Beneficial Owners and Management, and Proposal No.
• 4 Approval of the Corcept Therapeutics Incorporated 2024 Incentive Award Plan Incentive Award Plan Information in the Proxy Statement.
• The company states that the changes to amounts of percentage ownership as a result of using the correct number of outstanding shares are immaterial.
• A quorum requires a majority of the outstanding shares of the company's common stock entitled to vote at the Annual Meeting to be present in person or by proxy.
• Previously submitted proxy cards can still be used, and stockholders who have already voted do not need to take further action.

Sentiment

Score: 7

Explanation: The document is a neutral correction of information, indicating attention to detail and transparency, but not necessarily impacting the company's overall prospects positively or negatively.

Positives

• The company promptly corrected an error in its proxy statement, ensuring accurate information for stockholders.
• The company explicitly stated that the correction does not materially affect the percentage ownership of key stakeholders.

Management Comments

• The company urges stockholders to vote their shares prior to the Annual Meeting.

Industry Context

This announcement is a routine correction to a proxy statement, a common occurrence in corporate governance.

Stakeholder Impact

• The correction ensures that stockholders have accurate information for voting purposes.

Next Steps

• Stockholders are encouraged to vote their shares prior to the Annual Meeting on May 17, 2024.

Key Dates

Keywords

proxy statement, Corcept Therapeutics, shares outstanding, annual meeting, stockholders, correction